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OBJECTIVES: In Brazil, health insurance plans (HI) must pay for anticancer intra-
venous (IV) chemotherapy (CHEMO) but not for those taken by mouth (PO). Erlotinib
(E) is a PO CHEMO used to treat lung cancer 2nd or 3rd line. Our aim was to establish
the budgetary impact of the adoption of E, when compared to the IV competitors
docetaxel (D) and pemetrexed (P) for the HI in Brazil. METHODS: We searched
Evidencias Database for patients eligible for the use of E, in the year of 2008. This
database has information from 2 million of users of 14 HI. Then, we calculated the
costs of the IV chemo actually used. A simulation of the costs if E were adopted was
carried out. Many different sensitivity analyses were performed, according to the
line of treatment in which E was administered and the proportion changing from IV
to the PO option. RESULTS: We found 285 records of patients that were suitable for
the use of E. The cost of IV CHEMO was US$2,293,000. If E replaced the treatment for
all patients, the cost would be reduced to US$1,067,000, resulting in a economy of
US$1,222,000 (54%) of the total. If instead of replacing the IV option, E was used as
an additional line of treatment, an increase of US$635,000 in total costs would
occur. In a sensitivity analysis, that can reflect the practice, where 50% of the
patients would receive E instead of P or D in 2nd line, and 30% would receive E in 3rd
line, the adoption of E would result in an economy of US$295,000. CONCLUSIONS:
The adoption of E for the treatment of lung cancer in Brazil can be cost-saving for
HI.
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OBJECTIVES: To examine variation in real world health care utilization (HCU) and
costs associated with management of brain metastasis (BrMts) by primary malig-
nancy type. METHODS: A retrospective analysis utilized claims-data from a na-
tional health insurer, identifying patients18 yrs with2 claims7 days apart for
BrMets (ICD-9 198.3x) from January 2004 to April 2010. The index date was the date
of the first BrMets claim. Continuous enrollment (CE) in the health plan for 6
months before (baseline) and 1 month after (follow-up) index date was required;1
month follow-up was permitted if due to death. Excluding primary brain tumors,
baseline CE data (1993 to the index date) was examined to identify the initial pri-
mary malignancy. HCU (inpatient stays, office, outpatient and ER visits) and all-
cause per-patient per-month (PPPM) costs were examined. RESULTS: A total of
1031 lung and 395 breast cancer patients, and 93 with melanoma were included.
Baseline Charlson comorbidity score was not significantly different. Mean age at
BrRMets diagnosis was highest for lung (60yr) compared to breast cancer (55yr) and
melanoma (56yr)[p-value0.01]. Rates of HCU (events/person-month) were signif-
icantly different for melanoma, breast and lung cancer patients: 0.28 versus 0.17
and 0.24 for inpatient stays; 3.16 versus 3.87 and 3.94 for office visits; 2.84 vs. 2.69
and 2.80 for outpatient visits [p-value0.01]. Total costs PPPM were highest for
melanoma ($21,373) compared to breast ($17,933) and lung cancer ($15,199) [p-
value0.001]. Inpatient costs PPPM represented the largest portion of medical costs
(44%-50%), but were not significantly different across cohorts: melanoma ($9397),
breast ($8781) and lung cancer ($7628). Pharmacy costs PPPM were highest among
melanoma ($1555) then breast ($737) and lung cancer ($720) [p-value 0.001].
CONCLUSIONS: Variation was observed in HCU and costs among BrMets patients
based on initial primary tumor type. Analyses of cost studies on BrMets patients
need to take this into consideration.
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OBJECTIVES: To estimate direct costs associated to grades 3-4 adverse events (AEs)
management treatment of metastatic renal cell carcinoma (mRCC) with targeted
therapies (sorafenib, sunitinib, pazopanib, bevacizumab, everolimus and tem-
sirolimus) and to perform a comparative analysis from public and private health-
care perspectives, in Brazil. METHODS: A systematic literature review was con-
ducted to identify grades 3-4 AEs related to targeted therapies. To obtain direct
costs related to AEs management, procedures were created from national guide-
lines and expert validation. Total cost for each drug was calculated, considering a
six-month time horizon. Only direct medical costs were considered, expressed in
2011 Brazilian reals (BRL). Unit costs were obtained from Brazilian official lists. As
no head-to-head trials were found, indirect comparison in second-line targeted
therapy was performed according to NCCN guideline for everolimus (grade 1 rec-
ommendation) versus sorafenib and sunitinib (grade 2A) and temsirolimus (grade
2B). Bevacizumab (grade 2B) was excluded as data was available only for the asso-
ciation with IFN. In the base case, grades 3-4 incidence rates were obtained from
phase III clinical trials and varied in sensitivity analysis based on results obtained
in meta-analyses or observational studies. RESULTS: When compared to NCCN 2A
recommendation grade for second-line targeted therapy, everolimus is cost-saving
in base case and sensitivity analysis: versus sorafenib, there are savings ranging
from 5BRL to 717BRL and from 96BRL to 5841BRL in public and private perspectives,
respectively; versus sunitinib, savings vary from 153BRL to 681BRL and from
1778BRL to 5136BRL in public and private perspectives, respectively. Everolimus
was cost-saving due to easily manageable AEs and their frequencies.
CONCLUSIONS: Considering grades 1 and 2 NCCN recommendation for mRCC sec-
ond-line targeted therapies, everolimus represents the highest quality of evidence
and is also considered the lowest cost option for the management of associated AEs
from public and private healthcare perspectives, in Brazil.
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OBJECTIVES: Assessing the adverse events costs of comparable regimens
(sunitinib vs bevacizumab) in context of budget impact analysis in Croatian setting.
METHODS: Authors have assessed costs and outcomes of bevacizumab and
sunitinib via systematic review, performed in January 2011. Survival rates, inci-
dence and prevalence was assessed via Croatian National Cancer Registry, and the
model was verified with Monte Carlo simulations. Direct drug, adverse events and
treatment costs were calculated in kuna/per patient yearly according to price list-
ings of National Institute for Health Insurance. Local data was verified with struc-
tured interviews gathered with Croatian oncologists (N6) involved in this indica-
tion in their daily practice. Focus of the analysis was the drug cost and the adverse
events treatment cost. RESULTS: Sunitinib has showed costly side effects such as
neutropenia, trombocitopenia, hypothiroidism and cardiovascular complications.
The cost of adverse events (aforementioned) for sunitinib per patient yearly is 3.904
HRK (535 EUR), whereas for bevacizumab is 1.404 HRK (192 EUR). Bevacizumab
demonstrated significantly lower adverse events costs than sunitinib. Overall bud-
get impact (from payers perspective) when bevacizumab is introduced equals
-29.753,52 HRK (-4075 EUR) of savings yearly per patient.CONCLUSIONS:At current
costs, head to head drug price comparison demonstrates that bevacizumab is less
costly, demonstrating dominant ability to reduce costs due to less frequent and
less costly adverse events, whereas in budget impact context introducing bevaci-
zumab brings savings.
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OBJECTIVES: Spaepen et al. (The Oncologist 2008;13:596–607) published a cost
analysis comparing darbepoetin-alfa (DARB), epoetin-alfa (EPO-A) and epoetin-
beta (EPO-B) in the treatment of chemotherapy-induced anaemia in 2393 patients.
Data were derived from the IMS Hospital Disease Database, a longitudinal database
in secondary care unique to Belgium. The objectives of this study were to assess the
applicability of that analysis in the Spanish setting, and to evaluate differences in
cost between ESAs in Spain. METHODS: To adapt the Belgian data for Spain, dis-
crepancies in epidemiology and treatment patterns were examined, and costs were
replaced with Spanish-specific unit costs. Adjusting for tumour-specific incidence
and chemotherapy use, costs were analyzed using a mixed-effects model stratify-
ing for propensity score quintiles as in Spaepen 2008. Data sources included Euro-
stat, national cancer registries, IMS sales data, treatment guidelines, and reim-
bursement guidelines and lists. RESULTS: The Spanish and Belgian populations
were similar in terms of age, gender, ESA use and blood transfusions. Adjusting for
chemotherapy use and the relative weight (incidence Spain/ incidence Belgium) of
four pre-specified cancer types [haematological (1.2094), lung (0.6716), female
breast (0.5654) and female genital (0.9589)], total costs (meanSE) with DARB were
26% lower compared with EPO-A (p0.0001) and 20% lower compared with EPO-B
(p0.0019). Anaemia-related costs were 29% and 17% lower in DARB patients than
in EPO-A (p0.0001) and EPO-B (p0.0226) respectively. The mean duration of treat-
ment was 40.632.39 days for DARB; 53.591.25 for EPO-A and 52.392.54 for
EPO-B. CONCLUSIONS: By using published epidemiologic and treatment pattern
data, it was possible to adapt the Belgian Hospital database to the Spanish popu-
lation. Total and anaemia-related costs were lowest in patients receiving DARB
compared with EPO-A or EPO-B. These findings are consistent with those from the
Belgian analysis.
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OBJECTIVES: Spaepen et al. (the Oncologist 2008;13:596–607) published a cost-
analysis comparing darbepoetin-alfa (DARB), epoetin-alfa (EPO-A) and epoetin-
beta (EPO-B) in the treatment of chemotherapy-induced anaemia, using propensity
score matching. The study was performed using IMS Hospital Disease Database
(2003-2005, a longitudinal database unique to Belgium containing individual pa-
tient/admission-level data on diagnoses, procedures, and pharmaceuticals. Given
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the limited availability of databases reporting the same information in Italy, the
objectives of this study were to assess the applicability of the Belgian analysis, and
to estimate cost differences between ESAs in Italy.METHODS: To adapt the Belgian
data for the Italian setting, costs were replaced with Italian-specific costs, and
discrepancies in epidemiology and treatment patterns were examined. Adjusting
for country discrepancies, costs were analyzed using a mixed-effects model strat-
ifying for propensity score quintiles as in Spaepen et al. Sources included Eurostat,
national cancer registries, IMS sales data, treatment and reimbursement guide-
lines, and reimbursement public tariffs. RESULTS: The Italian and Belgian popula-
tions were similar in terms of age, gender, ESA use and blood transfusions. The
Belgian dataset was adjusted to reflect the incidence of haematological, lung, fe-
male breast and female genital cancers. No major differences between countries
were found regarding the use of ESAs or blood transfusions. In Italy, total costs
(meanSE) were €10,546873 for DARB versus €14,063745 and €13,274910 for
EPO-A (p0.0001) and EPO-B (p0.0008), respectively. Anaemia-related costs were
€3,144211 for DARB versus €5,049119 and €3,656230 for EPO-A (p0.0001) and
EPO-B (p0.0935). ESA costs were €2,475187 for DARB versus €4,241115 and
€3,115203 for EPO-A (p0.0001) and EPO-B (p0.0139). CONCLUSIONS: Total and
anaemia-related costs were lowest in patients receiving DARB compared with
EPO-A and EPO-B in Italy. These findings are consistent with those from the Belgian
analysis. Adapting Belgian data to Italy is feasible when accounting for patient and
treatment characteristics and costs.
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OBJECTIVES: Capecitabine (C) is approved in Brazil to treat colorectal cancer CRC,
and can replace the combination of 5fluorouracl (5FU) and folinic acid (FA) in many
chemotherapy (CHEMO) combination. There are restrictions to their use in the
private sector in Brazil, as oral (PO) CHEMO is not covered by health insurance plans
(HI). For many patients and physicians, a PO option is preferred over the intrave-
nous (IV) . Our aim was to study the budgetary impact linked to the use of C for the
treatment of CRC in HI. METHODS: We searched Evidencias Database for CRC
patients eligible for the use of C, in the year of 2008. This database has information
from over 2 million of users of 14 HI. We calculated the costs of the IV chemo
actually used (mainly combinations of 5FU-FA with oxaliplatin and irinotecan). We
calculated the costs of the drug used and, when appropriate, the infusion pump to
deliver 5FU by continuous infusion. Then, based on the real data of each individual
patient, we calculated the costs if C replaced 5FU-FA in the CHEMO. We assumed
both treatments would have the same efficacy, as reported in the literature.
RESULTS: We found 315 records of CRC patients that used IV Chemo and could
replace it by C. These patients received 2706 cycles of treatment and had an actual
total cost of US$7,237,000 (85% of them refers to the CHEMO drugs only). If C replace
5FU-FA in the IV CHEMO, the total cost would drop 9.5%, to US$6,804,000, mainly
due to the exclusion of the need of an infusion pump. CONCLUSIONS: The use of C
to treat CRC is linked to a smaller cost than the IV alternative in the private health
plans in Brazil.
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OBJECTIVES: Lung cancer is one of the most common cancers in the world. Stan-
dard curative therapy includes surgical resection of the primary tumour. Under-
standing how to combine best clinical outcomes for the most efficient use of re-
sources is important. We undertook a systematic review of the costs related to
managing early stage lung cancer to summarize the body of literature from the
global community.METHODS:An electronic literature search of EMBASE, MEDLINE
and HEALTHSTAR was performed (January 2000-August 1, 2010). The search terms
“Lung Cancer” and “Costs and Cost Analysis” or “Economics” were used. Two re-
viewers independently evaluated articles and consensus was achieved for all dis-
cordant evaluations. Data were abstracted using a standardized abstraction form.
Costs are reported in 2010 Canadian dollars. RESULTS: The literature search iden-
tified 3654 abstracts; 25 articles were included and the research spanned 13 coun-
tries. The majority (15/25) of the studies performed cost identification studies; the
remainder included 9 cost-effectiveness and 1 cost-utility analyses. Prospective
research was performed in only one study. Just over 50% (13/25) of the studies
reported a perspective, while 14/25 specified a time horizon for cost and health
outcome collection. Overall costs for treating early NSCLC ranged from $24,040 (no
recurrence) to $97,774 (persistent recurrence). The mean costs per patient for sur-
gery ranged from $88 (lobectomy chest drain equipment) to $92,967 (thoracotomy
lobectomy). CONCLUSIONS: The literature varies in adherence to optimal assess-
ment methodology, and room for improvement is evident. Costs vary by treatment
modality, yet few comparisons of available options exist for this population. Fur-
ther comparisons of population-based clinical and economic outcomes are neces-
sary in order to understand the burden of early lung cancer. This systematic review
of the costs of early lung cancer may help to inform the methodologies and costs for
future cost-effectiveness evaluations.
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OBJECTIVES: To compare the costs associated to second-line chemotherapies for
adNSCLC in France. Three therapies, docetaxel, pemetrexed and erlotinib are cur-
rently marketed in France for second-line management of advanced non-small-
cell lung cancer (adNSCLC). Published studies showed no statistically differences
between these treatments in term of efficacy (median progression-free survival or
survival), but there are few data on the costs of these therapies. METHODS: A
cost-minimization analysis was based on an indirect comparison of the results of
two prospective randomized French clinical trials (GFPC05-06 and CYTAR) in sec-
ond-line setting. Costs were estimated in the perspective of the French National
Sickness Fund and included direct treatments costs (excluding transports) and
in-patients costs both for treatment administration and potential adverse events.
All costs were estimated on a 100 days period. RESULTS: Studied population in-
cluded 145 patients treated with erlotinib, 75 patients treated with docetaxel and 75
with pemetrexed. Characteristics of patients were assumed to be similar. Overall,
the median direct costs of the second line chemotherapies/100 management days
were: 9,009€ (IQR: 8,403-12,291) for docetaxel, 14,229€ (IQR: 12,718-20,099) for pem-
etrexed and 7,134€ (IQR: 6,752-8669) for erlotinib. Two by two, total costs differ-
ences between compared chemotherapies were all statistically significant
(p0.001). The cost breakdowns among drug costs, in-patient stays for drug deliv-
ery, tests and supportive care and adverse events were respectively 85%, 0%, 0%,
15% (erlotinib), 73%, 6%, 6%, 15% (pemetrexed), and 59%, 20%, 7%, 14% (docetaxel).
CONCLUSIONS: Costs of second-line therapies for adNSCLC appeared to be slightly
lower using erlotinib as compared with docetaxel and pemetrexed due to lower
administration costs. However, this study was based only on an indirect compar-
ison and head to head trials are required to confirm such a conclusion.
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OBJECTIVES: An economic evaluation was undertaken to compare the treatment
cost of patients on darbepoetin alfa (DA) 500 mcg once every 3 weeks (Q3W) and 150
mcg weekly (QW), epoetin-alfa (EA) 40,000 IU QW, epoetin-beta (EB) 30,000 IU QW
and 3-times weekly (TIW) in the management of chemotherapy-induced anaemia
(CIA) in Greece. METHODS: : The analysis was based on a decision tree model
reflecting the local management of patients, driven primarily by their response to
therapy (measured in terms of an increase in haemoglobin concentration 2 g/Dl).
As therapies are assumed to be of similar efficacy, a cost-minimisation analysis
was undertaken considering National Health Services and patient transportation
costs. Different data on the dose and cost of drugs, and frequency of therapy and
response rates, were obtained from the published literature, expert opinions and
registries. The model was probabilistic and was used to run Monte Carlo simula-
tions to compensate for uncertainty. Results correspond to 2011 costs. RESULTS:
The mean total cost per patient treated with DA-Q3W was €2951 (95% Uncertainty
Interval (UI): €2912-2992), DA-QW €3192 (95%UI: €3075-3308), EA-QW €3781 (95%UI:
€3646-3914), EB-TIW €4908 (95%UI: €4563-5251), and EB-QW €3956 (95%UI: €3821-
4089). Cost-savings associated with DA-Q3W were: 8% relative to DA-QW; 22% to
EA-QW; 40% to EB-QW; and 25% to EB-TIW. The mean cost per response to DA-Q3W
was €3999 (95%UI: €3760-€4241); to DA-QW €4326 (95%UI: €4036-4639); to EA-QW
€5560 (95%UI: €5322-5790); to EB-TIW €7219 (95%UI: €6699-7734) and to EB-QW
€5818 (95%UI: €5575-6051). CONCLUSIONS: The present economic analysis indi-
cates that DA-Q3W and DA-QW may be associated with lower cost in comparison
with other options for the treatment of patients with CIA in Greece. Of the two
DA-based schemes, DA-Q3W appears to be associated with lower therapy cost.
Research funded by Genesis Pharma.
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OBJECTIVES:To assess the impact of brain metastasis (BrMets) on health care costs
and survival among metastatic NSCLC patients in a geographically diverse com-
mercially insured US population. METHODS: Retrospective analyses were con-
ducted using a US commercial administrative claims database linking data from a
lung cancer registry and mortality records from the Social Security Administration
Death Master File (2005-2010). Two cohorts were formed – a) with BrMets, and b)
without BrMets. Healthcare cost (hospitalization, ambulatory and pharmacy) and
resource use (hospitalization, emergency {ER} and ambulatory visits) were com-
pared using a generalized linear model (diagnosis ¡end of follow-up); a Cox pro-
portional hazard model estimated impact on survival. All models adjusted for stage
at diagnosis, pre-diagnosis comorbidity, age, and gender. RESULTS: A total of 584
metastatic NSCLC patients were included (mean 60.5 years/56.3% male): 247 (42.3%)
had claims-based evidence of BrMets and were more likely to have been diagnosed
with stage IV disease (62.8% vs. 52.2% without BrMets). Overall survival was shorter
among patients with evidence of BrMets (median 13.5 vs. 17.0 months; HR1.29,
p001); health plan enrollment duration was similar (median 11.7 months). With
similar lengths of follow-up, average health care costs following diagnosis of
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